China's state drug administration approved Chongqing Genrix Biopharmaceutical's (SHA:688443) clinical trial for a combination of the GR1803 injection with anti-CD38 monoclonal antibody, according to a Thursday filing with the Shanghai bourse.
The trial will test the drug combination in adult patients with relapsed/refractory multiple myeloma or cancer of plasma cells, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments